184results about How to "Good clinical value" patented technology

The invention discloses a monoclonal antibody of Japanese encephalitis virus and Zika virus and application of the monoclonal antibody, and relates to the technical field of immunology and molecular virology. The monoclonal antibody or the antigen binding fragment thereof comprises a VH CDR1, a VH CDR2 and a VH CDR3 of which the amino acid sequences are as shown in SEQ ID NO: 1-3, and a VL CDR1, a VL CDR2 and a VL CDR3 of which the amino acid sequences are as shown in SEQ ID NO: 4-6. A large number of experimental studies show that the monoclonal antibody can specifically recognize and target extracellular regions of E proteins of the Japanese encephalitis virus and the Zika virus, can block combination of the E proteins and cell surface receptors, and shows efficient virus neutralizing capacity. Therefore, the antibody provided by the invention is particularly suitable for being used for diagnosing, preventing and / or treating diseases related to Japanese encephalitis virus and Zika virus infection.

The invention discloses a range-limited light-operated anti-tumor composite hydrogel drug reservoir and a preparation method and application thereof.The light-responsive drug-loaded nano hydrogel is loaded into a temperature-sensitive hydrogel system to form the range-limited hydrogel drug reservoir with light-operated drug release, the preparation method comprises the steps that PEG, LA and GA are added into a three-necked flask for an oil bath reaction, and the temperature-sensitive hydrogel system is obtained; after the reaction, purifying and freeze-drying to obtain a PLGA-PEG-PLGA block copolymer; the PLGA-PEG-PLGA segmented copolymer is dissolved in ultrapure water, and a PLGA-PEG-PLGA sol is obtained; and dissolving the drug-loaded PDA (at) P (NIPAAm-co-AM) nano hydrogel into the PLGA-PEG-PLGA sol, so as to obtain the confined light-operated anti-tumor composite hydrogel drug reservoir. The confined light-operated anti-tumor composite hydrogel drug reservoir has light-responsive drug delivery performance, not only has space-time controllability of drug release, but also weakens the problems of photothermal effect and the like in light-assisted therapy, so that accurate tumor therapy can be realized.

The invention relates to the technical field of microorganisms, in particular to a bacteriophage capable of splitting a high-risk escherichia coli clone strain and targeting multiple serotypes and application of the bacteriophage. The invention discloses a bacteriophage capable of splitting a high-risk escherichia coli clone strain and targeting multiple serotypes, the bacteriophage is named as Escherichia phage vBEcoM32M3Y, the bacteriophage is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.45969. The invention further discloses a preparation method of the bacteriophage. The bacteriophage disclosed by the invention is low in MOI, good in stability, good in cracking activity, free of drug-resistant and virulence genes in a genome sequence, and relatively good in clinical application value.

The invention relates to an induced sputum single-cell suspension as well as a preparation method and application thereof. The preparation method comprises the following steps: obtaining a filtered sputum suspension to be detected; performing low-temperature centrifugation; centrifuging the sample, and removing supernate; precipitating the cells, adding DPBS which does not contain calcium and magnesium ions, lightly mixing with a transfer pipette, and repeatedly inverting the transfer pipette to enable the cell pellets to suspend again; filtering and collecting filtrate; performing low-temperature centrifugation on the filtrate collected in the previous step, and removing supernate without damaging cell precipitation; adding a proper amount of DPBS free of calcium and magnesium ions into the cell precipitate obtained in the previous step, and gently mixing with a pipette; and adjusting the volume of the suspension to obtain the target cell concentration, thereby obtaining the single-cell suspension. According to the present invention, the induced sputum single cell suspension is prepared, such that a large amount of sputum single cells can be enriched, and the obtained induced sputum single cell suspension can be used for single cell transcriptome sequencing so as to well detect the gene expression condition of the sputum cells, such that the airway inflammation pathogenesis can be easily explored, and the clinical treatment can be easily guided.

The invention is suitable for the technical field of biological medicine, and provides an excess drug treatment cell as well as a preparation method and application thereof. According to the invention, human umbilical cord mesenchymal stem cells (H.P.M) treated by excessive prednisone (PRED) are used as a carrier of PRED, and the excessive PRED treatment enables the human umbilical cord mesenchymal stem cells to lose proliferation ability and activity, but retains the ability of the human umbilical cord mesenchymal stem cells to target an inflammation site. The H.P.M can accurately deliver PRED to an inflammation part, so that pH-sensitive controlled release is realized, the treatment effect is improved, and the side effect of systemic application of PRED is greatly reduced. Due to the good drug loading capacity and release stability, the effectiveness and stability of drug delivery are further improved. The excess drug treatment method can be applied to other types of cells, and other drugs can be selected as the excess drug for treating the cells, so that a breakthrough is brought to treatment of gouty arthritis, and a new way is opened up for treatment of other diseases.

The invention discloses a novel multi-adaptive guide sheath and application thereof. The novel multi-adaptive guide sheath comprises a guide sheath tube body, a guide sheath tube tail end joint connected with the guide sheath tube body, and an optional guide sheath tail end connector which is quickly assembled and separated from the guide sheath tube tail end joint through a quick conversion joint; the quick conversion connector comprises a first valve body connected with a connector at the tail end of the guide sheath tube and a second valve body connected with a connector at the tail end of the optional guide sheath. A first valve element moving front and back in the axial direction of the first valve body is arranged in a cavity in the rear portion of the first valve body, and a second valve element moving front and back in the axial direction of the second valve body is arranged in the second valve body. When the second valve body is inserted into the cavity in the front of the first valve body and then locked by the locking mechanism, the first valve element and the second valve element are connected, and hollow channels in the first valve element and the second valve element are communicated. The guide sheath tube is changed into a replaceable accessory, and the tail end connector can be quickly connected with various devices, so that the adaptability and the use efficiency of the guide sheath are improved, and the operation efficiency and the safety are improved.

The invention discloses magnesium-containing mesoporous active bioglass with drug sustained release, immunoregulation and bone metabolism regulation effects and application thereof. The drug-loaded MBGN is prepared by doping Mg ions and loading drugs, and the drug-loaded MBGN has good biocompatibility and can be decomposed in an acid environment to achieve controllable slow release of the drugs; on the other hand, released ions such as Si, Ca and Mg have a certain immunoregulation function, polarization of macrophages from M1 type to M2 type is promoted, inflammatory response is reduced, differentiation and maturation of osteoclasts are inhibited, and meanwhile, the released ions and drugs carried in mesopores play a synergistic effect, so that a good treatment effect is achieved. The drug-loaded MBGN provided by the invention has various biological properties, can overcome the defects of low drug loading rate, insufficient anti-inflammatory effect and the like when the existing mesoporous bioactive glass material is applied clinically, and has a good application prospect.

The invention discloses a fluralan nanostructure lipid carrier and a preparation method thereof, and belongs to the technical field of insecticide preparation, fluralan nanostructure lipid carrier semisolid cream can be orally taken or externally applied and is used for preventing and treating ectoparasitic diseases of pets such as dogs and cats; quantitative polyol is added into the water phase to be compounded with the lipid, so that the performance of the nano-structure lipid carrier is improved, the nano-structure lipid carrier system is more stable and high in encapsulation efficiency, release and absorption of a main drug in the nano-structure lipid carrier are improved, the problem of solubility of the fluralana is solved, bioavailability is improved, and the preparation method is suitable for industrial production. The traditional Chinese medicine composition promotes the medicine to play a better curative effect in vivo, so that the treatment effect is improved while the dosage of pets is reduced, the safety of the medicine is improved, the damage to the pets is reduced, and the traditional Chinese medicine composition has remarkable clinical application value.

The invention belongs to the technical field of image processing, and particularly relates to a passive domain adaptive eye fundus image segmentation method based on adaptive mask and curvature regularization, which comprises the following steps: constructing a teacher-student self-training framework, and generating a pseudo tag by using a weak enhancement teacher model to guide student model training, an adaptive mask consistency strategy is introduced in the training process, adaptive mask processing is carried out on a target domain image, the mask proportion and size are adaptively adjusted according to the sample difficulty and the size of a pseudo-label area, a model is guided to keep prediction consistency under the shielding condition, and thus the pseudo-label reliability and the context modeling capability are improved; meanwhile, by introducing an average negative curvature regularization constraint, an irregular boundary in a prediction result is suppressed, the smoothness and structural continuity of a segmentation result are enhanced, and finally the precision and generalization ability of the model in a cross-device and cross-dataset fundus image segmentation task are improved.

The invention belongs to the technical field of medicine, and particularly relates to a PI3K gamma inhibitor, a preparation method thereof and application of the PI3K gamma inhibitor in medicine. The invention provides a PI3K gamma inhibitor as shown in a formula (Ia), (IIa), (Ib) or (IIb) as well as a composition and application thereof. The compound can be used for treating or preventing diseases or symptoms related to abnormal expression of a PI3K gamma signaling pathway. # imgabs0 #

The invention relates to an absorbable double-layer membrane for guiding oral gingival tissue regeneration and repair and a preparation method thereof, the double-layer membrane comprises a compact layer and a loose layer, the compact layer is formed by PCL fibers, and the loose layer is formed by recombinant collagen / polyhydroxyalkanoate blend fibers. Wherein the PCL compact layer can be well stitched, and plays a protective role during open type healing. The recombinant collagen / polyhydroxyalkanoate blend fiber loose layer solves the problems of hydrophobicity of polyhydroxyalkanoate and low strength and too fast degradability of single recombinant collagen, and is more beneficial to fixation of blood clots and ingrowth of soft tissue cells, and inflammatory response is reduced. According to the double-layer membrane disclosed by the invention, the degradation time and the strength are highly matched with gingival tissues by optimizing the components, the proportion and the like, so that the regeneration and the repair of the gingival tissues can be better promoted, and the double-layer membrane has a remarkable clinical application value.

The invention provides a crystal form of a free alkali of a compound I, a salt of the compound I and a crystal form of the salt of the compound I. In addition, the invention also relates to application of the crystal form and the salt form of the compound I in treating related diseases and symptoms such as tumors or cancers. Some salt forms, such as sulfate, phosphate, acetate, pamoate and the like, provided by the invention have better clinical application value, and can be used as an excellent alternative form for subsequent drug development.

The invention discloses a hydrogel sustained-release system loaded with a 3D cultured MSC source exosome and a preparation method and application thereof, and belongs to the technical field of biomedicine, the exosome is the 3D cultured MSC source exosome, MSC comprises bone marrow MSC, and hydrogel comprises GelMA. According to the invention, the methacrylated gelatin (GelMA) hydrogel is used as a carrier to load the 3D culture MSC source exosome, and an anti-inflammatory and repair-promoting exosome-hydrogel sustained release system is successfully established and is applied to treatment of corneal injury repair. Researches prove that the 3D cultured MSC exosome can relieve inflammatory response and stromal scar formation after corneal injury and promote corneal epithelium regeneration. The hydrogel is used as a carrier, so that continuous slow release of the functional exosome on the surface of the cornea is realized, the action time of the functional exosome is prolonged, the treatment effect of the functional exosome is improved, corneal stroma regeneration can be promoted, and the repair of corneal injury is comprehensively promoted.

The invention provides a composite preservative for fecal microorganisms and metabolites thereof and a same-tube multi-omics joint inspection integrated technology. The composite preservative comprises the following main components: cetyltrimethylammonium bromide (CTAB), ammonium chloride (NH4Cl) and phosphate buffer salt (PBS), the stability of microorganisms and metabolites thereof in the excrement sample in the room-temperature storage and transportation process can be kept, and the extraction efficiency of deoxyribonucleic acid (DNA) of the microorganisms in the excrement sample is guaranteed. In addition, by adding a treatment reagent, the influence of the preservative component on metabolite detection is eliminated, and the response and ionization efficiency of the excrement sample metabolite in the mass spectrum are remarkably improved, so that the sensitivity and accuracy of a detection result are improved. The method not only solves the problem of timeliness of excrement sampling, but also provides a technical basis and thought for feasibility research of the same-tube multi-omics of excrement samples, and has wide scientific research and clinical application prospects.

The present invention belongs to the field of coronary artery medical technology, and discloses a non-invasive method for calculating CFR, comprising S1, reconstructing a three-dimensional model of coronary arteries and generating a grid; S2, setting boundary conditions of the model; S3, simulating CFD configuration of hemodynamics; S4, calculating CFR; the present invention realizes non-invasive CFR calculation based on coronary artery CTA images, does not require invasively measured blood flow (such as blood pressure, flow velocity) data, only requires CTA images, and analyzes the CTA images through a proposed algorithm and indirectly calculates the CFR. The method for calculating CFR realizes the unity of economy and safety, and the obtained CFR value is accurate, can effectively evaluate the coronary artery vascular function, and is helpful for medical staff to specify the best treatment plan.

The invention relates to the field of biological medicine, and provides an ionizable lipid compound capable of activating an STING signal channel and application of the ionizable lipid compound. The invention specifically provides an ionizable lipid compound which has a natural adjuvant effect and can induce generation of I-type interferon gene expression by activating an STING pathway, so that APC activation and antigen presentation are promoted, and the immune response ability of a body is enhanced. And a method for synthesizing the ionizable lipid compound from a ketone compound, an amine compound and an isonitrile compound. The invention also provides an application of the ionizable lipid compound in preparation of lipid nanoparticles, the lipid nanoparticles formed by the ionizable lipid can deliver nucleic acid molecules into cells, the expression level of nucleic acid drugs in vivo can be significantly improved, and the immune response of the organism can be stimulated. Ionizable lipid compound having the structure shown: # imgabs0 #

The invention relates to a construction method and application of a spontaneous and persistent ventricular tachycardia animal model, in particular to a spontaneous and persistent ventricular tachycardia rat model based on MYL4 gene defect and myocardial infarction induction. The model is constructed by utilizing the synergistic effect of double pathological factors of MYL4 gene conserved gene defects and acquired myocardial infarction, the induction rate of the model is greater than or equal to 90%, the spontaneous duration time reaches 1-3 min, and the method is obviously superior to an existing construction method for inducing the spontaneous and continuous ventricular tachycardia model. The model can simulate the pathophysiological process of ventricular tachycardia after human MYL4 gene related cardiovascular diseases combined with myocardial infarction, provides general technical support for ventricular arrhythmia pathogenesis research, drug screening and medical instrument research and development, and has wide scientific research and clinical transformation value.

This invention relates to the field of biotechnology, and in particular to a primer-probe combination for detecting methylation sites in cancer and its applications. This invention is the first to discover that abnormal methylation at specific sites of the TRIB3 gene is significantly associated with the occurrence and development of colorectal cancer, and abnormal methylation at specific sites of the MAPT gene is significantly associated with the occurrence and development of gastric cancer. This correlation has not been publicly reported in the prior art, possessing novelty and significant clinical application value. The primer-probe combination provided by this invention is used to detect the methylation status of the TRIB3 gene or the MAPT gene in a sample. Specifically, when the primer-probe combination is used to detect the methylation level at specific sites of the TRIB3 gene, it can be used for the auxiliary diagnosis, early screening, or risk assessment of colorectal cancer; when the primer-probe combination is used to detect the methylation level at specific sites of the MAPT gene, it can be used for the auxiliary diagnosis, early screening, or risk assessment of gastric cancer.

This invention relates to a method for constructing a prognostic assessment model for acute myeloid leukemia (AML) with NPM1 mutations. The method includes the following steps: (1) collecting and detecting gene mutation data required for the prognostic assessment system of AML patients with NPM1 mutations, including the mutation status of FLT3-ITD, IDH1, and SRSF2 genes; (2) assigning values ​​according to the mutation status of FLT3-ITD, IDH1, and SRSF2; (3) substituting the values ​​assigned in step (2) into the formula: mNPM1 AML risk score = 1.077 × FLT3-ITD - 0.800 × IDH1 + 1.512 × SRSF2, and performing grouped and parallel prognostic assessments on the calculated values. This invention provides a prognostic assessment model for AML with NPM1 mutations, providing important guidance for the treatment of such patients and having good clinical application value.

The invention provides a traditional Chinese medicine composition for treating esophageal cancer, the traditional Chinese medicine composition is prepared from the following medicines in parts by weight: 10-20 parts of codonopsis pilosula, 10-20 parts of garden balsam seed, 6-10 parts of gecko, 20-40 parts of salvia chinensis, 10-20 parts of prepared arisaema consanguineum schott, 10-20 parts of roasted fructus chebulae and 10-20 parts of trifoliate orange, the invention discloses a preparation method of the traditional Chinese medicine composition, and also discloses application of the traditional Chinese medicine composition and an anti-tumor medicine in preparation of a medicine for treating esophageal cancer. The traditional Chinese medicine composition is reasonable in formula principle and remarkable in effect, and has good clinical application value and social significance.

Provided in the present invention is an antibody against human CD3 or an antigen-binding fragment thereof; also provided are a nucleic acid molecule encoding the antibody, an expression vector expressing the antibody and a host cell, as well as a method for producing the antibody. In addition, also provided in the present invention are a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, a use thereof in the preparation of a drug, and a use of the drug as a drug for the prevention and / or treatment of various diseases, including tumors, organ transplantation and autoimmune diseases.

The present invention relates to anti-SARS-CoV-2RBD monoclonal antibodies and applications. The monoclonal antibodies targeting SARS-CoV-2RBD provided by the present invention are different from existing commercial monoclonal antibodies and can specifically bind to highly conserved antigenic epitopes located in SARS-CoV-2RBD. 350 VYAWN 354 , the antigenic epitope is highly conserved among different SARS-CoV-2 strains, and is not affected by the "upward" and "downward" conformational changes of the S protein RBD; experiments have shown that the anti-SARS-CoV-2RBD monoclonal antibody provided by the present application is an effective neutralizing antibody, which can be used for the development of drugs to prevent and / or treat diseases caused by SARS-CoV-2 infection, and has good clinical application value. The monoclonal antibody of the present invention has a clear recognition epitope, can effectively recognize various conformational forms of SARS-CoV-2 or SARS-CoV-2S protein, and has high affinity, strong specificity, and good stability, providing a new tool for the prevention, detection and treatment of SARS-CoV-2.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine externally-applied ointment for treating postoperative complications of mixed hemorrhoids as well as a preparation method and application of the traditional Chinese medicine externally-applied ointment. The externally-applied traditional Chinese medicine ointment for treating postoperative complications of mixed hemorrhoids comprises the following raw materials in parts by weight: 150-250 parts of calcined gypsum, 27-45 parts of bryozoatum, 9-15 parts of indigo naturalis, 36-60 parts of borneol, 30-60 parts of sesame oil and 500-850 parts of vaseline, has the effects of clearing heat and promoting diuresis, relieving swelling and pain, and healing sores and stopping bleeding, can treat main symptoms after the mixed hemorrhoids, and has no toxic or side effects. Complications such as postoperative pain, wound edema, anal pendant expansion, bleeding and the like are effectively relieved, and wound healing is accelerated.

The invention belongs to the field of gene engineering, and provides a primer and probe combination, a kit and a method for detecting DNA methylation of an OTX1 gene and a PENK gene. According to the invention, a high-sensitivity 3 'UTR region of the OTX1 gene and a first exon region of the PENK gene are selected, a methylated and non-methylated primer and probe combination is designed, and the OTX1 gene and the PENK gene are subjected to joint detection, so that the detection sensitivity and accuracy are greatly improved. Meanwhile, the TaqMan probe with two marked ends is selected, so that the sensitivity, specificity and accuracy of detection are improved, and the kit has a very good clinical application value.

The application selects highly conservative and excellent interspecies specificity UL49A gene as a target from multiple strains of HSV-1 and related herpes simplex virus (HSV-2, EBV, CMVh and VZV) coding sequences through bioinformatics whole genome alignment, designs and selects specific primer probe combination 124F / 124R / 124P, and establishes a HSV-1 probe method fluorescence quantitative PCR detection system targeting UL49A gene. Based on the primer probe group, the HSV-1 detection kit can be prepared, which is suitable for clinical biological samples such as lesion secretions, aqueous humor and blood, especially can provide a rapid, accurate and high-sensitivity etiological diagnosis scheme for HSV-1 related keratitis, and has good clinical application value.

The present invention discloses colorectal cancer metabolic markers and their application in diagnosing colorectal cancer. The present invention collects samples from colorectal cancer patients and healthy controls, performs metabolomics analysis, and discovers key metabolic markers related to colorectal cancer and important metabolic pathways related thereto. The present invention discovers for the first time that the above-mentioned metabolic markers show significant differences between colorectal cancer patients and healthy people. Model validation shows that the above-mentioned metabolic markers have high AUC values ​​for diagnosis, and have good predictive effects on early colorectal cancer patients and colorectal precancerous lesions, indicating that the above-mentioned metabolic markers have good clinical use and promotion value.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical preparation for treating hyperplasia of mammary glands and a preparation method thereof, and the pharmaceutical preparation for treating hyperplasia of mammary glands comprises a drug-loaded microneedle layer, a backing layer connected with the drug-loaded microneedle layer and a medical blank adhesive plaster adhered to the backing layer. The prepared medicine preparation is a traditional Chinese medicine compound microneedle patch, the designed traditional Chinese medicine compound has the effects of soothing liver-qi stagnation, promoting blood circulation to remove blood stasis, reducing swelling and removing stasis and the like, a micro-emulsion system formed through the synergistic effect of the traditional Chinese medicine compound and a soluble microneedle matrix has the effects of moisturizing, diminishing inflammation, resisting bacteria and resisting oxidation, the skin permeability of the medicine is improved, and meanwhile, the effect of improving the skin quality is achieved. The drug sustained release and skin protection effects are realized, the effective concentration of the drug at the hyperplasia part of mammary glands can be maintained, and the treatment effect is enhanced.

The application discloses application of a PCSK9 inhibitor Alirocumab in prevention and treatment of gallbladder stones. The application is characterized in that, through pharmacological experiments in a mouse gallbladder stone model, the PCSK9 inhibitor Alirocumab can effectively reduce the content of cholesterol in mouse bile, and can prevent the formation of mouse gallbladder stones and dissolve the formed gallbladder stones. After administration, under ultrasonic monitoring, the diameter of the stones gradually decreases with the increase of the administration time. Therefore, the application provides a new drug for effectively preventing and treating cholesteric gallbladder stones. The PCSK9 inhibitor Alirocumab provided by the application has good clinical application value and application prospect as a drug for preventing and treating cholesteric gallbladder stones.

The invention belongs to the field of colorectal cancer detection, and particularly relates to an excrement metabolite marker combination for early diagnosis of colorectal cancer and application. The method comprises the following steps: firstly, screening to obtain an excrement metabolite biomarker combination for early diagnosis of the colorectal cancer, and measuring the content of markers for early diagnosis of the colorectal cancer; secondly, according to the invention, a model for early diagnosis or prediction of the colorectal cancer is constructed through random forest, linear regression and other models based on the specificity of a metabolome detection result, early diagnosis of the colorectal cancer is realized, and the kit has the advantages of low cost, convenience in detection, high accuracy, good sensitivity and strong specificity, and is suitable for popularization and application. The kit can avoid pain, discomfort and complications caused by enteroscope invasive examination, obviously reduces the false positive rate of early diagnosis of colorectal cancer, and is widely used for early diagnosis of colorectal cancer.

The invention relates to the technical field of disease diagnosis, in particular to application of ZCCHC2 in sicca syndrome diagnosis and systemic lupus erythematosus distinguishing.